The Study of the Validation of General Evaluation Score (GES) in the Prediction of Hepatocellular Carcinoma Risk Among Patients With Advanced Fibrosis and Cirrhosis Who Achieved Sustained Virological Response for Hepatitis C Virus After Direct Acting Antiviral Drugs
Conditions: Hepatocellular Carcinoma Interventions: Diagnostic Test: General Evaluation Score (GES) Sponsors: Egyptian Liver Hospital Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 22, 2024 Category: Research Source Type: clinical trials
Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma
Conditions: Advanced Hepatocellular Carcinoma; Anti-PD1/PDL1 Antibody; Bevacizumab Interventions: Procedure: Locoregional therapy; Drug: Bevacizumab; Drug: Atezolizumab; Drug: Tislelizumab; Drug: Toripalimab; Drug: Sintilimab; Drug: Camrelizumab Sponsors: Sun Yat-sen University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 21, 2024 Category: Research Source Type: clinical trials
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.
Conditions: Breast Cancer; Lung Cancer; Melanoma; Head and Neck Cancer; Urothelial Carcinoma; Colorectal Cancer; Liver Metastases; Lung Metastases Interventions: Genetic: Cohort A: primarily operable disease, candidate to adjuvant; Genetic: Cohort B: locally advanced disease; Genetic: Cohort C: metastatic disease; Genetic: Cohort D: Progressive disease; Genetic: Cohort E: Hematological neoplasms; Genetic: Cohort F: Toxicity Sponsors: European Institute of Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
Conditions: Advanced Hepatocellular Carcinoma Interventions: Drug: TQB2223 injection; Drug: Penpulimab Injection Sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 20, 2024 Category: Research Source Type: clinical trials
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
Conditions: Hepatocellular Carcinoma; Circulating Tumor Cell; Recurrence; Surgery Interventions: Diagnostic Test: circulating tumor cells Sponsors: Zhujiang Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 19, 2024 Category: Research Source Type: clinical trials
Effectiveness and Safety of Lenvatinib Combined With Chinese Herbal Medicine for Patients With Unresectable Hepatocellular Carcinoma: A Real-world Study in China
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Drug: Chinese Herbal Medicine Sponsors: Guangzhou University of Chinese Medicine Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2024 Category: Research Source Type: clinical trials
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
Conditions: HCC Interventions: Drug: PD-1 monoclonal antibody and lenvatinib; Drug: PD-1 monoclonal antibody Sponsors: Chen Xiaoping Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)
Conditions: Hepatocellular Carcinoma Interventions: Radiation: Stereotactic body radiotherapy; Drug: Sintilimab Sponsors: Sun Yat-sen University; Fifth Affiliated Hospital, Sun Yat-Sen University; Ningbo Medical Center Lihuili Eastern Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk
Conditions: Liver Cirrhosis; Hepatocellular Carcinoma Interventions: Procedure: Abdominal US; Procedure: AMRI Sponsors: So Yeon Kim Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy of NRT6003 in Patients With Unresectable Hepatocellular Carcinoma
Conditions: Unresectable Hepatocellular Carcinoma Interventions: Drug: NRT6003 Injection Sponsors: Chengdu New Radiomedicine Technology Co. LTD. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Association of GSTP1 and CYP2B6 With Response and Survival Outcomes in HCC Patients.
Conditions: Hepatocellular Carcinoma Interventions: Drug: Doxorubicin Sponsors: Damanhour University; King Abdullah Bin Abdulaziz University Hospital; King Saud Bin Abdulaziz University for Health Sciences Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Phase 2 Study of WGI-0301 in Combination With Sorafenib for Advanced HCC
Conditions: Advanced Hepatocellular Carcinoma (HCC) Interventions: Drug: WGI-0301 at MTD/RP2D dose IV infusion, QW; Drug: WGI-0301 at MTD/RP2D -1 dose IV infusion, QW; Drug: Sorafenib 400 mg PO, BID continuously; Drug: Sorafenib 400 mg PO, BID Sponsors: Zhejiang Haichang Biotech Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 13, 2024 Category: Research Source Type: clinical trials
Open Versus Laparoscopic Ablation of Liver Malignancies
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Liver Metastases Interventions: Procedure: Laparoscopic ablation; Procedure: Open ablation Sponsors: Rigshospitalet, Denmark Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 12, 2024 Category: Research Source Type: clinical trials
Open Versus Laparoscopic Ablation of Liver Malignancies: a Randomized, Controlled Multicenter Trial
Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma; Liver Metastases Interventions: Procedure: Laparoscopic ablation; Procedure: Open ablation Sponsors: Rigshospitalet, Denmark Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 11, 2024 Category: Research Source Type: clinical trials
Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study
Conditions: Advanced Hepatocellular Carcinoma Interventions: Drug: Rituximab+PD-1 or PD-L1 inhibitors+targeted therapy Sponsors: Tianjin Medical University Cancer Institute and Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
